276 related articles for article (PubMed ID: 24762993)
21. [Detection of BCR/ABL, MLL/AF4 and TEL/AML1 hybrid genes and monitoring of minimal residual disease in pediatric patients with acute lymphoblastic leukemia].
Trka J; Zuna J; Haskovec C; Brabencová A; Kalinová M; Muzíková K; Paukertová R; Hrusák O; Zemanová Z; Michalová K; Starý J
Cas Lek Cesk; 1999 Jan; 138(1):12-7. PubMed ID: 10953429
[TBL] [Abstract][Full Text] [Related]
22. Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome.
Stams WA; Beverloo HB; den Boer ML; de Menezes RX; Stigter RL; van Drunen E; Ramakers-van-Woerden NL; Loonen AH; van Wering ER; Janka-Schaub GE; Pieters R
Leukemia; 2006 Mar; 20(3):410-6. PubMed ID: 16424874
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukemia.
Takahashi Y; Horibe K; Kiyoi H; Miyashita Y; Fukuda M; Mori H; Nozaki C; Hasegawa S; Kawabe T; Kato K; Kojima S; Matuyama T; Naoe T
J Pediatr Hematol Oncol; 1998; 20(3):190-5. PubMed ID: 9628428
[TBL] [Abstract][Full Text] [Related]
24. Interphase FISH on TEL/AML1 positive acute lymphoblastic leukemia relapses--analysis of clinical relevance of additional TEL and AML1 copy number changes.
Peter A; Heiden T; Taube T; Körner G; Seeger K
Eur J Haematol; 2009 Nov; 83(5):420-32. PubMed ID: 19594616
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy and prognostic factors of the chemotherapy regimen of CCLG-ALL-2008 on pediatric acute lymphoblastic leukemia with ETV6-RUNX1 rearrangement].
Liu F; Chen XJ; Guo Y; Yang WY; Chen X; Zhang XY; Zhang RR; Ren YY; Zhu XF
Zhonghua Xue Ye Xue Za Zhi; 2020 Nov; 41(11):896-902. PubMed ID: 33333691
[No Abstract] [Full Text] [Related]
26. Molecular quantification of response to therapy and remission status in TEL-AML1-positive childhood ALL by real-time reverse transcription polymerase chain reaction.
Seeger K; Kreuzer KA; Lass U; Taube T; Buchwald D; Eckert C; Körner G; Schmidt CA; Henze G
Cancer Res; 2001 Mar; 61(6):2517-22. PubMed ID: 11289124
[TBL] [Abstract][Full Text] [Related]
27. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
Stams WA; den Boer ML; Beverloo HB; Meijerink JP; van Wering ER; Janka-Schaub GE; Pieters R
Clin Cancer Res; 2005 Apr; 11(8):2974-80. PubMed ID: 15837750
[TBL] [Abstract][Full Text] [Related]
28. Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia.
de Haas V; Oosten L; Dee R; Verhagen OJ; Kroes W; van den Berg H; van der Schoot CE
Br J Haematol; 2000 Dec; 111(4):1080-6. PubMed ID: 11167743
[TBL] [Abstract][Full Text] [Related]
29. Relapse of TEL-AML1--positive acute lymphoblastic leukemia in childhood: a matched-pair analysis.
Seeger K; von Stackelberg A; Taube T; Buchwald D; Körner G; Suttorp M; Dörffel W; Tausch W; Henze G
J Clin Oncol; 2001 Jul; 19(13):3188-93. PubMed ID: 11432885
[TBL] [Abstract][Full Text] [Related]
30. Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection.
Panzer-Grümayer ER; Cazzaniga G; van der Velden VH; del Giudice L; Peham M; Mann G; Eckert C; Schrauder A; Germano G; Harbott J; Basso G; Biondi A; van Dongen JJ; Gadner H; Haas OA
Clin Cancer Res; 2005 Nov; 11(21):7720-7. PubMed ID: 16278392
[TBL] [Abstract][Full Text] [Related]
31. Persistence of TEL-AML1 transcript in acute lymphoblastic leukemia in long-term remission.
Endo C; Oda M; Nishiuchi R; Seino Y
Pediatr Int; 2003 Jun; 45(3):275-80. PubMed ID: 12828580
[TBL] [Abstract][Full Text] [Related]
32. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
33. The therapeutic efficacy of pediatric ALL patients with MLL gene rearrangement treated with CCLG-ALL2008 protocol.
Sun YN; Hu YX; Gao L; Xiao PF; Lu J; Wu SY; Wang M; Shao XJ; Zhou CY; Ling J; Li JQ; Pan J; Gao J; Hu SY
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):6020-6029. PubMed ID: 30280786
[TBL] [Abstract][Full Text] [Related]
34. ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol.
Wang Y; Zeng HM; Zhang LP
Ital J Pediatr; 2018 Aug; 44(1):94. PubMed ID: 30115129
[TBL] [Abstract][Full Text] [Related]
35. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01.
Loh ML; Goldwasser MA; Silverman LB; Poon WM; Vattikuti S; Cardoso A; Neuberg DS; Shannon KM; Sallan SE; Gilliland DG
Blood; 2006 Jun; 107(11):4508-13. PubMed ID: 16493009
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of patients with TEL-AML1-positive acute lymphoblastic leukemia with single or multiple fusions.
Al-Sweedan SA; Neglia JP; Steiner ME; Bostrom BC; Casey T; Hirsch BA
Pediatr Blood Cancer; 2007 May; 48(5):510-4. PubMed ID: 16763978
[TBL] [Abstract][Full Text] [Related]
37. TEL/AML-1 fusion gene. its frequency and prognostic significance in childhood acute lymphoblastic leukemia.
Jamil A; Theil KS; Kahwash S; Ruymann FB; Klopfenstein KJ
Cancer Genet Cytogenet; 2000 Oct; 122(2):73-8. PubMed ID: 11106814
[TBL] [Abstract][Full Text] [Related]
38. TEL/AML1 rearrangement and the prognostic significance in childhood acute lymphoblastic leukemia in Hong Kong.
Tsang KS; Li CK; Chik KW; Shing MM; Tsoi WC; Ng MH; Lau TT; Leung Y; Yuen PM
Am J Hematol; 2001 Oct; 68(2):91-8. PubMed ID: 11559948
[TBL] [Abstract][Full Text] [Related]
39. NOTCH1 mutations are associated with favourable long-term prognosis in paediatric T-cell acute lymphoblastic leukaemia: a retrospective study of patients treated on BCH-2003 and CCLG-2008 protocol in China.
Gao C; Liu SG; Zhang RD; Li WJ; Zhao XX; Cui L; Wu MY; Zheng HY; Li ZG
Br J Haematol; 2014 Jul; 166(2):221-8. PubMed ID: 24690100
[TBL] [Abstract][Full Text] [Related]
40. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
